adonertinib   Click here for help

GtoPdb Ligand ID: 14609

Synonyms: compound 11 [US20190225610]
Compound class: Synthetic organic
Comment: Adonertinib is the INN for an epidermal growth factor receptor inhibitor with antineoplastic potential. Released in the WHO INN Proposed List 135 (July 2026), the chemical structure is claimed in Nanjing Chuangte Pharmaceutical's patent US20190225610A1 [1]. The company pipeline lists FHND9041 as an irreversible, third-generation EGFR inhibitor that is designed to target EGFR in lung tumours with sensitive mutations such as T790M/L858R (double mutant). We can surmise that adonertinib may be the INN for FHND9041.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 11
Topological polar surface area 84.8
Molecular weight 525.65
XLogP 2.05
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C=CC(=O)NC1=C(C=C(C(=C1)NC2=NC=CC(=N2)C3=CN4CCCC5=CC=CC3=C54)OC)N(C)CCN(C([2H])([2H])[2H])C
Isomeric SMILES [2H]C([2H])([2H])N(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=CC(=N2)C3=CN4CCCC5=C4C3=CC=C5)OC
InChI InChI=1S/C30H35N7O2/c1-6-28(38)32-24-17-25(27(39-5)18-26(24)36(4)16-15-35(2)3)34-30-31-13-12-23(33-30)22-19-37-14-8-10-20-9-7-11-21(22)29(20)37/h6-7,9,11-13,17-19H,1,8,10,14-16H2,2-5H3,(H,32,38)(H,31,33,34)/i2D3
InChI Key CLXOEYRLLVMPJB-BMSJAHLVSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Zhu Y, Liu Z, Feng C, Hu S, Chen H, Bai E, Wang J, Shi J. (2019)
Deuterated 3-(4,5-substituted aminopyrimidine)phenyl derivatives and use thereof.
Patent number: US20190225610A1. Assignee: Nanjing Chuangte Pharmaceutical Technology Co Ltd. Priority date: 18/09/2017. Publication date: 25/07/2019.